Pharmacotherapy of Obesity: An Updated Overview

被引：0
作者：
El Hussein, Mohamed [1 ,2 ,3 ]
Favell, Daniel [4 ]
机构：
[1] Mt Royal Univ, Fac Hlth Community & Educ, Sch Nursing & Midwifery, Calgary, AB, Canada
[2] Univ Alberta, Fac Nursing, Calgary, AB, Canada
[3] Rockyview Gen Hosp, Coronary Care Unit, Med Cardiol, Calgary, AB, Canada
[4] Alberta Hlth Serv, Gen Med Palliat Care Unit 73, Calgary, AB, Canada
来源：
JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2023年 / 19卷 / 09期
关键词：
GLP-1; agonists; liraglutide; naltrexone/bupropion; obesity; pharmacotherapy; semaglutide; WEIGHT-LOSS; LIRAGLUTIDE; ADULTS; OVERWEIGHT; EFFICACY; SAFETY; IMPACT;
D O I：
10.1016/j.nurpra.2023.104750
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Obesity is an emerging epidemic in Canada that poses a threat to public health. Pharmaceutical weight management is an option for managing excess weight. In this review, we briefly discuss the pathophysiology of obesity and present the current pharmacotherapy for its treatment, focusing on orlistat, naltrexone/ bupropion, liraglutide, and semaglutide. In addition, we briefly discuss upcoming pharmacotherapies for the management of obesity.(c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页数：6
相关论文
共 38 条
[1]   Clinical Impact of Liraglutide as a Treatment of Obesity [J].
Alruwaili, Heshma ;
Dehestani, Babak ;
le Roux, Carel W. .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2021, 13 :53-60
[2]   Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies [J].
Atlantis, Evan ;
Sahebolamri, Mehdi ;
Cheema, Birinder S. ;
Williams, Kathryn .
OBESITY REVIEWS, 2020, 21 (11)
[3]   Trends and projections of obesity among Canadians [J].
Bancej, C. ;
Jayabalasingham, B. ;
Wall, R. W. ;
Rao, D. P. ;
Do, M. T. ;
de Groh, M. ;
Jayaraman, G. C. .
HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE, 2015, 35 (07) :109-112
[4]   Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review [J].
Bliddal, H. ;
Leeds, A. R. ;
Christensen, R. .
OBESITY REVIEWS, 2014, 15 (07) :578-586
[5]   The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies [J].
Blonde, L. ;
Russell-Jones, D. .
DIABETES OBESITY & METABOLISM, 2009, 11 :26-34
[6]  
Blouin C, 2016, CAN J PUBLIC HEALTH, V107, pE507, DOI [10.17269/cjph.107.5585, 10.17269/CJPH.107.5585]
[7]  
Centers for Disease Control and Prevention, 2022, Obesity BasicsJune 3
[8]   Pharmacotherapy of obesity: an update on the available medications and drugs under investigation [J].
Chakhtoura, Marlene ;
Haber, Rachelle ;
Ghezzawi, Malak ;
Rhayem, Caline ;
Tcheroyan, Raya ;
Mantzoros, Christos S. .
ECLINICALMEDICINE, 2023, 58
[9]   Semaglutide for the treatment of obesity [J].
Chao, Ariana M. ;
Tronieri, Jena S. ;
Amaro, Anastassia ;
Wadden, Thomas A. .
TRENDS IN CARDIOVASCULAR MEDICINE, 2023, 33 (03) :159-166
[10]   Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial [J].
Davies, Melanie J. ;
Bergenstal, Richard ;
Bode, Bruce ;
Kushner, Robert F. ;
Lewin, Andrew ;
Skjoth, Trine Vang ;
Andreasen, Arne Haahr ;
Jensen, Christine Bjorn ;
DeFronzo, Ralph A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (07) :687-699
1234